---
title: "3D Medicines Inc. (01244.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01244.HK.md"
symbol: "01244.HK"
name: "3D Medicines Inc."
industry: "Biotechnology"
---

# 3D Medicines Inc. (01244.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.3d-medicines.com](https://www.3d-medicines.com) |

## Company Profile

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous inje...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:12.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 47 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -8.13% |  |
| Net Profit YoY | 62.47% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.33 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.05B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 486.20M |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -21.55% | E |
| Profit Margin | -37.58% | E |
| Gross Margin | 83.79% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -8.13% | D |
| Net Profit YoY | 62.47% | B |
| Total Assets YoY | -7.94% | E |
| Net Assets YoY | -16.70% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -266.10% | D |
| OCF YoY | -8.13% | D |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.37 | C |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 44.65% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 3D Medicines Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-21.55%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-37.58%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "83.79%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-8.13%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "62.47%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.94%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-16.70%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-266.10%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-8.13%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "44.65%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BEONE MEDICINES (HK.6160) | C | A | B | C | A | B |
| 02 | INNOVENT BIO (HK.1801) | B | A | C | B | A | B |
| 03 | 3SBIO (HK.1530) | A | B | C | A | C | B |
| 04 | BIOCYTOGEN-B (HK.2315) | A | A | C | D | B | B |
| 05 | HBM HOLDINGS-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.66 | 24/70 | - | - | - |
| PB | 1.33 | 7/70 | 2.19 | 1.62 | 1.13 |
| PS (TTM) | 2.13 | 6/70 | 3.61 | 2.60 | 1.98 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/01244.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01244.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01244.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.